We validated KDM6A/KDM6B as the target of GSK-J4 since KDM6A/KDM6B genetic depletion had a remarkably similar effect to GSK-J4 on cisplatin-mediated anti-tumor activity and transcriptome alterations. The gene discussed is KDM6B; the disease is neoplasm.